Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2941 - Overall survival (OS) by platelet count at baseline in patients with hepatocellular carcinoma (HCC) treated with sorafenib (SOR) in the SHARP and AP trials and regorafenib (REG) in the RESORCE trial

Date

09 Sep 2017

Session

Poster display session

Presenters

Gerold Meinhardt

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

G. Meinhardt1, Y. De Sanctis2, M. Leberre3, K. Nakajima4

Author affiliations

  • 1 Clinical Development Oncology, Bayer HealthCare Pharmaceuticals, 07981 - Whippany/US
  • 2 Medical Writing And Statistics, Oncology Sbu, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 3 Pharmaceuticals Division, Bayer HealthCare SAS, Loos/FR
  • 4 Global Medical Affairs, Bayer HealthCare Pharmaceuticals, Whippany/US
More

Resources

Abstract 2941

Background

SOR and REG significantly improved OS versus placebo (PBO) in patients with unresectable HCC: SOR in the first-line setting in both the SHARP (median OS: 10.7 SOR vs 7.9 months PBO, HR 0.69; P 

Methods

Patients with advanced HCC who received treatment in SHARP (SOR n = 299, PBO n = 303; NCT00105443), AP (SOR n = 150, PBO n = 76; NCT00492752), and RESORCE (REG n = 374, PBO n = 193; NCT01774344) were included in the analysis. Patients were subgrouped according to a baseline platelet count of > 150 × 109/L and ≤150 × 109/L. OS (HR and its 95% CI) was evaluated using a Cox proportional hazards model.

Results

In SHARP, 180 patients (60%) treated with SOR and 199 (66%) receiving PBO had a baseline platelet count of > 150 × 109/L; 84 (56%) with SOR and 46 (61%) with PBO in AP; 163 (44%) with REG and 91 (47%) with PBO in RESORCE. Baseline variables were generally similar between subgroups for AP; in RESORCE, more patients had hepatitis C in the >150 × 109/L platelet count group; in SHARP, the lower platelet count group had more patients with ECOG PS 0 and BCLC B, fewer patients with macrovascular invasion and extrahepatic spread, less tumor burden, and more cases of hepatitis C. In SHARP and AP, a lower platelet count at baseline was associated with improved OS, but this was not observed in RESORCE. Both SOR and REG improved OS over PBO in both subgroups.Table:

706P

Trial (active drug)Platelet countnMedian OS for active drug, daysMedian OS PBO, daysHR* (95% CI)
SHARP (SOR)>150 × 109/L3792902180.81 (0.63, 1.04)
≤150 × 109/L2214422970.60 (0.42, 0.85)
AP (SOR)>150 × 109/L1301861190.62 (0.42, 0.93)
≤150 × 109/L952271660.78 (0.47, 1.31)
RESORCE (REG)>150 × 109/L2543262300.57 (0.41, 0.78)
≤150 × 109/L3183132410.78 (0.58, 1.04)
*

HR 

Conclusions

The analysis indicates that platelet count may be a prognostic factor for first-line HCC but not for second-line HCC patients. SOR and REG are effective treatment options in HCC regardless of platelet count at baseline.

Clinical trial identification

NCT01774344

Legal entity responsible for the study

Bayer

Funding

Bayer

Disclosure

G. Meinhardt, Y. De Sanctis: Employment and stock ownership: Bayer. M-A. LeBerre: Employment: Bayer. K. Nakajima: Employment and ownership: Bayer.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.